ArticleFrontiers in immunology2024

Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.

Shu-Han Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.